Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence TATSEYQTFFNPR
Primary information
sequence IDSeq_8085
Peptide sequenceTATSEYQTFFNPR
CancerPDF_ID CancerPDF_ID102, CancerPDF_ID1836, CancerPDF_ID9894, CancerPDF_ID12377,
PMID16896061,21136997,21533267,26992070
Protein NameProthrombin,Prothrombin,Prothrombin,Prothrombin
UniprotKB Entry NameTHRB_HUMAN,THRB_HUMAN,THRB_HUMAN,THRB_HUMAN
FluidSerum,Serum,Serum,Serum
M/Z781.29,1560.72087,781.36,1560.7209
Charge2,1,2,NA
Mass (in Da)1560.72,NA,NA,1561.731127
fdrNA,NA,NA,NA
Profiling TechniqueMALDI-TOF,LC-MS,LC-MS,LC-MS
Peptide Identification techniqueQ/TOF MS/MS,LC-MS-MS/MS,LC/MS/MS,LC-MS/MS
Quantification TechniqueNA,LC-ESI-MS,Multiple Reaction Monitoring,NA
Labelled/Label FreeLabel Free,Label Free,Label Free,Label Free
FDRNA,NA,1.49,FDR 1 %
CancerPDF_ID CancerPDF_ID102, CancerPDF_ID1836, CancerPDF_ID9894, CancerPDF_ID12377,
p-Value1.00E-05,NA,NA,NA
SoftwareMASCOT,MASCOT(v. 2.2.01),MASCOT,SEQUEST and Maxquant
Length13,13,13,13
Cancer TypeMetastatic thyroid carcinomas,Colorectal cancer,Lung adenocarcinoma,Melanoma
DatabaseNCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4),SwissProt Database
ModificationNA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples
RegulationNA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 7 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples."
ValidationIndependent validation,Leave One out Cross validation,MRM-based validation of 19 candidates,na
Sensitivity95% on independent dataset,NA,NA,NA
Specificity95% on independent dataset,NA,NA,NA
AccuracyNA,NA,NA,NA
Peptide AtlasPeptideAtlas
IEDB